Improvement strategies for successful next-generation sequencing analysis of lung cancer

Papers of special note have been highlighted as: • of interest; •• of considerable interest

References

• 1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J. Clin. 69(1), 7–34 (2019).
  MedlineGoogle Scholar
• 2. Barlesi F, Mazieres J, Merlio JP et al. Routine molecular profiling of patients with advanced non-small-cell lung cancer: results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT). Lancet 387(10026), 1415–1426 (2016).
  Medline CASGoogle Scholar
• 3. Thomas A, Liu SV, Subramaniam DS, Giaccone G. Refining the treatment of NSCLC according to histological and molecular subtypes. Nat. Rev. Clin. Oncol. 12(9), 511–526 (2015).
  Medline CASGoogle Scholar
• 4. Masters GA, Temin S, Azzoli CG et al. Systemic therapy for stage IV non-small-cell lung cancer: American Society of Clinical Oncology Clinical Practice guideline update. J. Clin. Oncol. 33(30), 3488–3515 (2015).
  Medline CASGoogle Scholar
• 5. Ettinger DS, Aisner DL, Wood DE et al. NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J. Natl Compr. Canc. Netw. 16(7), 807–821 (2018).
  MedlineGoogle Scholar
• 6. Lindeman NI, Cagle PT, Aisner DL et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch. Pathol. Lab. Med. 142(3), 321–346 (2018).
  Medline CASGoogle Scholar
• 7. Riely GL. What, when, and how of biomarker testing in non-small cell lung cancer. J. Natl Compr. Canc. Netw. 15(5S), 686–688 (2017).
  MedlineGoogle Scholar
• 8. Fuller MY, Mody D, Hull A, Pepper K, Hendrickson H, Olsen R. Next-generation sequencing identifies gene mutations that are predictive of malignancy in residual needle rinses collected from fine-needle aspirations of thyroid nodules. Arch. Pathol. Lab. Med. 142(2), 178–183 (2018).
  Medline CASGoogle Scholar
• 9. Yoh K, Seto T, Satouchi M et al. Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre Phase 2 trial. Lancet Respir. Med. 5(1), 42–50 (2017). •• Evaluation of the efficacy of Vandetanib for lung cancer with RET fusion genes using the lung cancer genomic screening project for individualized medicine (LC-SCRUM) Japan screening.
  Medline CASGoogle Scholar
• 10. Ikemura S, Yasuda H, Matsumoto S et al. Molecular dynamics simulation-guided drug sensitivity prediction for lung cancer with rare EGFR mutations. Proc. Natl Acad. Sci. USA 116(20), 10025–10030 (2019). •• Drug study on EGFR exon 20 insertion using LC-SCRUM-Japan screening database.
  Medline CASGoogle Scholar
• 11. Kunimasa K, Tachihara M, Tamura D et al. Diagnostic utility of additional conventional techniques after endobronchial ultrasonography guidance during transbronchial biopsy. Respirology 21(6), 1100–1105 (2016).
  MedlineGoogle Scholar
• 12. Trisolini R, Cancellieri A, Tinelli C et al. Rapid on-site evaluation of transbronchial aspirates in the diagnosis of hilar and mediastinal adenopathy: a randomized trial. Chest 139(2), 395–401 (2011).
  MedlineGoogle Scholar
• 13. Kanda Y. Investigation of the freely available easy-to-use software ‘EZR’ for medical statistics. Bone Marrow Transplant. 48(3), 452–458 (2013).
  Medline CASGoogle Scholar
• 14. Endrullat C, Glokler J, Franke P, Frohme M. Standardization and quality management in next-generation sequencing. Appl. Transl. Genom. 10, 2–9 (2016).
  MedlineGoogle Scholar
• 15. Akkari Y, Smith T, Westfall J, Lupo S. Implementation of cancer next-generation sequencing testing in a community hospital. Cold Spring Harb. Mol. Case Stud. 5(3), a003707 (2019). • Review of next-generation sequencing (NGS) implementation and operations at community hospitals.
  MedlineGoogle Scholar
• 16. Jennings LJ, Arcila ME, Corless C et al. Guidelines for validation of next-generation sequencing-based oncology panels: A Joint Consensus Recommendation of the Association for Molecular Pathology and College of American Pathologists. J. Mol. Diagn. 19(3), 341–365 (2017).
  MedlineGoogle Scholar
• 17. Atanesyan L, Steenkamer MJ, Horstman A, Moelans CB, Schouten JP, Savola SP. Optimal fixation conditions and DNA extraction methods for MLPA analysis on FFPE tissue-derived DNA. Am. J. Clin. Pathol. 147(1), 60–68 (2017).
  Medline CASGoogle Scholar
• 18. Williams C, Ponten F, Moberg C et al. A high frequency of sequence alterations is due to formalin fixation of archival specimens. Am. J. Pathol. 155(5), 1467–1471 (1999).
  Medline CASGoogle Scholar
• 19. Amemiya K, Hirotsu Y, Oyama T, Omata M. Relationship between formalin reagent and success rate of targeted sequencing analysis using formalin fixed paraffin embedded tissues. Clin. Chim. Acta 488, 129–134 (2019).
  Medline CASGoogle Scholar
• 20. Hedegaard J, Thorsen K, Lund MK et al. Next-generation sequencing of RNA and DNA isolated from paired fresh-frozen and formalin-fixed paraffin-embedded samples of human cancer and normal tissue. PLoS ONE 9(5), e98187 (2014).
  MedlineGoogle Scholar
• 21. Guo Y, Wu J, Zhao S et al. RNA sequencing of formalin-fixed, paraffin-embedded specimens for gene expression quantification and data mining. Int. J. Genomics 2016, 9837310 (2016).
  MedlineGoogle Scholar
• 22. Iddawela M, Rueda O, Eremin J et al. Integrative analysis of copy number and gene expression in breast cancer using formalin-fixed paraffin-embedded core biopsy tissue: a feasibility study. BMC Genomics 18(1), 526 (2017).
  MedlineGoogle Scholar
• 23. Sparano JA, Gray RJ, Makower DF et al. Prospective validation of a 21-gene expression assay in breast cancer. N. Engl. J. Med. 373(21), 2005–2014 (2015).
  Medline CASGoogle Scholar
• 24. Amemiya K, Hirotsu Y, Goto T et al. Touch imprint cytology with massively parallel sequencing (TIC-seq): a simple and rapid method to snapshot genetic alterations in tumors. Cancer Med. 5(12), 3426–3436 (2016).
  Medline CASGoogle Scholar
• 25. Amemiya K, Hirotsu Y, Oyama T, Omata M. Simple and rapid method to obtain high-quality tumor DNA from clinical-pathological specimens using touch imprint cytology. J. Vis. Exp. 21(133), 56943 (2018).
  Google Scholar
• 26. Kage H, Kohsaka S, Shinozaki-Ushiku A et al. Small lung tumor biopsy samples are feasible for high quality targeted next-generation sequencing. Cancer Sci. 110(8), 2652–2657 (2019). • Studies of the success rate of NGS analysis when limited to bronchoscopic specimens
  Medline CASGoogle Scholar
• 27. Oezkan F, Herold T, Darwiche K et al. Rapid and highly sensitive detection of therapeutically relevant oncogenic driver mutations in EBUS-TBNA specimens from patients with lung adenocarcinoma. Clin. Lung Cancer 19(6), e879–e884 (2018).
  Medline CASGoogle Scholar
• 28. Fielding D, Dalley AJ, Bashirzadeh F et al. Diff-quik cytology smears from endobronchial ultrasound transbronchial needle aspiration lymph node specimens as a source of DNA for next-generation sequencing instead of cell blocks. Respiration 97(6), 525–539 (2019).
  Medline CASGoogle Scholar
• 29. Xie F, Zheng X, Mao X et al. Next-generation sequencing for genotyping of endobronchial ultrasound-guided transbronchial needle aspiration samples in lung cancer. Ann. Thorac. Surg. 108(1), 219–226 (2019).
  MedlineGoogle Scholar
• 30. Rodrigo MC, Martin DS, Redetzke RA, Eyster KM. A method for the extraction of high-quality RNA and protein from single small samples of arteries and veins preserved in RNA later. J. Pharmacol. Toxicol. Methods 47(2), 87–92 (2002).
  Medline CASGoogle Scholar
• 31. Wille M, Yin H, Lundkvist A, Xu J, Muradrasoli S, Jarhult JD. RNAlater((R)) is a viable storage option for avian influenza sampling in logistically challenging conditions. J. Virol. Methods 252, 32–36 (2018).
  Medline CASGoogle Scholar
• 32. Carithers LJ, Agarwal R, Guan P et al. The biospecimen preanalytical variables program: a multiassay comparison of effects of delay to fixation and fixation duration on nucleic acid quality. Arch. Pathol. Lab. Med. 143(9), 1106–1118 (2019).
  Medline CASGoogle Scholar
• 33. Jones W, Greytak S, Odeh H et al. Deleterious effects of formalin-fixation and delays to fixation on RNA and miRNA-Seq profiles. Sci. Rep. 9(1), 6980 (2019). • A detailed study of the impairment of formalin fixation on tissue RNA.
  MedlineGoogle Scholar
• 34. Drilon A, Oxnard G, Wirth L et al. PL02.08 registrational results of LIBRETTO-001: a Phase I/II trial of LOXO-292 in patients with RET fusion-positive lung cancers. J. Thorac. Oncol. 14(10), Supplement S6–S7 (2019).
  Google Scholar
• 35. Canon J, Rex K, Saiki AY et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature 575(7781), 217–223 (2019).
  Medline CASGoogle Scholar
• 36. Lanman BA, Allen JR, Allen JG et al. Discovery of a covalent inhibitor of KRAS(G12C) (AMG 510) for the treatment of solid tumors. J. Med. Chem. 63(1), 52–65 (2020).
  Medline CASGoogle Scholar